MPM BioImpact LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001687078
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2026 · 36 positions · Total reported value $1.30B · Top-10 concentration 49.3% · Updated 2026-11-17
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
Turnover: 78.3% · 9 new · 17 cut · 10 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -22.2% · vs SPY -24.3% · Prev Value $1.64B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -7.2% · vs SPY -9.4% · Latest Value $1.30B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2026 13F filing, MPM BioImpact LLC disclosed 36 equity positions with a combined reported value of $1.30B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were CGEM ($149.22M), AKTS ($94.15M), TVTX ($64.08M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+1.3pp) and away from Other (-1.3pp).
Versus the prior quarter, MPM BioImpact LLC opened 9 new positions, trimmed 17 and fully exited 10, a turnover rate of 78.3% of positions. The portfolio's overlap with the prior quarter was 59% of names.
The largest new positions opened in Q3 2026 were IOVA ($42.03M), IMCR ($36.45M), VIR ($31.41M).
Of the 10 positions fully exited versus the prior quarter, the largest were RVMD ($92.23M), ALMS ($56.82M), RARE ($47.35M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2026)
Fully Exited (vs previous quarter)
- RVMD REVOLUTION MEDICINES INC · prev qtr: $92.23M
- ALMS ALUMIS INC · prev qtr: $56.82M
- RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $47.35M
- DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $40.94M
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $31.29M
- SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $29.15M
- FBRX FORTE BIOSCIENCES INC · prev qtr: $20.98M
- TRDA ENTRADA THERAPEUTICS INC · prev qtr: $9.22M
Insider Transactions (Form 4)
Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 36 positions worth $1.30B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-106989 (status: Approved), registered 2016-01-04
- Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 14 private funds, of which 3 hedge funds
Portfolio Structure
- 36 positions · $1.30B reported value (Q3 2026)
- Top 10 holdings = 49.3% of reported value
- Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 11.5%
- Average position size: $36.09M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 9 new, 8 added, 17 reduced, 10 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
9.72M | $149.22M | 11.49% | Hold | |
| 2 |
|
4.84M | $94.15M | 7.25% | Hold | |
| 3 |
|
1.09M | $64.08M | 4.93% | Reduce | |
| 4 |
|
1.58M | $63.99M | 4.92% | Reduce | |
| 5 |
|
3.21M | $51.68M | 3.98% | Add | |
| 6 |
|
422.00K | $48.63M | 3.74% | Reduce | |
| 7 |
|
2.37M | $42.77M | 3.29% | Reduce | |
| 8 |
|
2.98M | $42.66M | 3.28% | Reduce | |
| 9 |
|
2.84M | $42.03M | 3.23% | New | |
| 10 |
|
1.34M | $40.63M | 3.13% | Reduce | |
| 11 |
|
90.58K | $37.44M | 2.88% | Reduce | |
| 12 |
|
909.69K | $36.96M | 2.85% | Reduce | |
| 13 |
|
1.20M | $36.45M | 2.81% | New | |
| 14 |
|
3.04M | $35.81M | 2.76% | Reduce | |
| 15 |
|
7.26M | $35.37M | 2.72% | Add | |
| 16 |
|
328.38K | $32.52M | 2.50% | Reduce | |
| 17 |
|
2.81M | $31.41M | 2.42% | New | |
| 18 |
|
1.96M | $31.31M | 2.41% | Add | |
| 19 |
|
3.85M | $31.01M | 2.39% | New | |
| 20 |
|
1.20M | $29.03M | 2.23% | Reduce | |
| 21 |
|
1.29M | $28.64M | 2.21% | New | |
| 22 |
|
352.68K | $27.72M | 2.13% | Add | |
| 23 |
|
197.63K | $27.26M | 2.10% | Reduce | |
| 24 |
|
5.18M | $27.24M | 2.10% | Add | |
| 25 |
|
300.00K | $24.99M | 1.92% | New | |
| 26 |
|
1.82M | $24.54M | 1.89% | Reduce | |
| 27 |
|
925.13K | $24.05M | 1.85% | Add | |
| 28 |
|
133.39K | $22.65M | 1.74% | Reduce | |
| 29 |
|
771.84K | $21.47M | 1.65% | New | |
| 30 |
|
4.45M | $18.51M | 1.43% | Reduce | |
| 31 |
|
4.29M | $18.15M | 1.40% | Add | |
| 32 |
|
1.13M | $13.42M | 1.03% | Reduce | |
| 33 |
|
1.86M | $13.16M | 1.01% | Add | |
| 34 |
|
1.67M | $11.37M | 0.88% | New | |
| 35 |
|
195.67K | $9.75M | 0.75% | Reduce | |
| 36 |
|
254.37K | $9.02M | 0.69% | New | |
FAQ
What did MPM BioImpact LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, MPM BioImpact LLC reported 36 equity positions worth $1.30B in aggregate; its largest disclosed positions were CGEM ($149.22M), AKTS ($94.15M), TVTX ($64.08M).
How large is MPM BioImpact LLC's portfolio?
MPM BioImpact LLC reported $1.30B of long equity holdings across 36 positions as of 2026-Q3. Top-10 holdings account for 49.3% of reported value.
What is MPM BioImpact LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.